Research Updates

Dr. Melissa Spencer provides update on development of an LGMD2A/R1 gene therapy

Melissa Spencer, PhD, Chair of the C3 Scientific Advisory Board and Professor of Neurology at UCLA, recently presented during a webinar hosted by the Muscular Dystrophy Association (MDA). The presentation, aimed at educating the public, gave an excellent background about genes, mutations, and adeno-associated vector (AAV)-based gene therapies. She highlights some of the latest advances in gene therapy technologies and provides an update on her program developing an AAV-based gene therapy for LGMD2A/R1. This project received funding from C3, the MDA, and the National Institutes of Health.

Read more about Dr. Spencer’s C3-funded gene therapy program here and MDA here

Recent Posts

  • New Research Grant Aims to Improve Understanding of Dominant Calpainopathy

    C3 is pleased to share that a research grant has been awarded to Drs. Ana Töpf, Jordi Diaz-Manera, and Volker Straub at the John Walton Muscular Dystrophy Research Centre at Newcastle University. This project, titled “Understanding the variable expression of dominant calpainopathies,” explores the molecular basis for LGMDD4, also known as dominant calpainopathy. The Challenges... Read More
    Jennifer Levy Grant Announcements

  • New research alert! Expert consortium publishes LGMD2A/R1 longitudinal data

    The GRASP-LGMD Consortium is a group of doctors, physical therapists, and clinical research coordinators who collaborate to measure how the symptoms of LGMD change over time. Studies like this, called Natural History Studies, are critical for the design of future clinical trials. The results of the Consortium’s LGMD2A/R1 study were recently published in the journal Neuromuscular Disorders.... Read More
    Jennifer Levy Research Updates